Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | DNPH1 | O43598 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706253 | 0.83 | P2RY12 (0.50) | P2RY12IMPDH2DNPH1 | |
| SCHEMBL17363546 | 0.81 | SIRT2 (0.58) | SIRT2SIRT1IMPDH2DNPH1 | |
| SCHEMBL16871847 | 0.81 | SIRT2 (0.58) | SIRT2SIRT1IMPDH2DNPH1 | |
| SCHEMBL17363547 | 0.81 | SIRT2 (0.58) | SIRT2SIRT1IMPDH2DNPH1 | |
| SCHEMBL17363544 | 0.75 | SIRT2 (0.51) | SIRT2SIRT1IMPDH2DNPH1 | |
| SCHEMBL19699266 | 0.72 | DNPH1 (0.46) | SIRT2SIRT1IMPDH2DNPH1 | |
| SCHEMBL18486379 | 0.71 | SIRT2 (0.37) | SIRT2SIRT1IMPDH2 | |
| SCHEMBL19699229 | 0.71 | POLB (0.56) | P2RY12IMPDH2DNPH1 | |
| SCHEMBL19699207 | 0.69 | DNPH1 (0.58) | SIRT2SIRT1IMPDH2DNPH1 | |
| SCHEMBL16871862 | 0.69 | HSD17B10 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | P2RY12 3118/4885SIRT2 4059/4885SIRT1 3870/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | P2RY12 3171/4885SIRT2 4066/4885SIRT1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.